Concepts (93)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Gonorrhea | 4 | 2020 | 12 | 1.760 |
Why?
|
| Neisseria gonorrhoeae | 3 | 2020 | 8 | 1.040 |
Why?
|
| Penicillins | 2 | 2020 | 11 | 0.740 |
Why?
|
| Anti-Bacterial Agents | 3 | 2020 | 324 | 0.740 |
Why?
|
| Osteomyelitis | 1 | 2020 | 22 | 0.720 |
Why?
|
| Azithromycin | 1 | 2020 | 15 | 0.720 |
Why?
|
| Arthritis, Infectious | 1 | 2020 | 24 | 0.720 |
Why?
|
| Naloxone | 1 | 2018 | 26 | 0.630 |
Why?
|
| Narcotic Antagonists | 1 | 2018 | 39 | 0.630 |
Why?
|
| Opioid-Related Disorders | 1 | 2018 | 54 | 0.600 |
Why?
|
| Microcephaly | 1 | 2017 | 3 | 0.590 |
Why?
|
| Disease Outbreaks | 1 | 2017 | 43 | 0.570 |
Why?
|
| Syphilis, Congenital | 1 | 2016 | 3 | 0.560 |
Why?
|
| Treponema pallidum | 1 | 2016 | 7 | 0.560 |
Why?
|
| Syphilis | 1 | 2016 | 10 | 0.560 |
Why?
|
| Anus Diseases | 1 | 2016 | 2 | 0.560 |
Why?
|
| Public Health | 1 | 2017 | 81 | 0.550 |
Why?
|
| Papillomaviridae | 1 | 2016 | 20 | 0.550 |
Why?
|
| Papillomavirus Infections | 1 | 2016 | 65 | 0.510 |
Why?
|
| HIV Infections | 2 | 2017 | 394 | 0.490 |
Why?
|
| Brain Abscess | 1 | 2010 | 4 | 0.380 |
Why?
|
| Ascomycota | 1 | 2010 | 4 | 0.380 |
Why?
|
| Mycoses | 1 | 2010 | 20 | 0.370 |
Why?
|
| Chlamydia Infections | 2 | 2020 | 10 | 0.320 |
Why?
|
| Humans | 12 | 2020 | 31976 | 0.260 |
Why?
|
| Drug Resistance, Bacterial | 2 | 2020 | 47 | 0.220 |
Why?
|
| Adult | 6 | 2020 | 9340 | 0.220 |
Why?
|
| Mycoplasma Infections | 1 | 2020 | 1 | 0.190 |
Why?
|
| Mycoplasma genitalium | 1 | 2020 | 1 | 0.190 |
Why?
|
| Urethritis | 1 | 2020 | 3 | 0.190 |
Why?
|
| Drug Resistance, Microbial | 1 | 2020 | 14 | 0.190 |
Why?
|
| Cefixime | 1 | 2020 | 4 | 0.180 |
Why?
|
| HIV Seronegativity | 1 | 2020 | 6 | 0.180 |
Why?
|
| Pharynx | 1 | 2020 | 14 | 0.180 |
Why?
|
| Tetracycline | 1 | 2020 | 13 | 0.180 |
Why?
|
| Ceftriaxone | 1 | 2020 | 14 | 0.180 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2020 | 80 | 0.180 |
Why?
|
| Point-of-Care Systems | 1 | 2020 | 44 | 0.170 |
Why?
|
| Male | 8 | 2020 | 19155 | 0.170 |
Why?
|
| Homosexuality, Male | 1 | 2020 | 84 | 0.160 |
Why?
|
| Drug Prescriptions | 1 | 2018 | 54 | 0.150 |
Why?
|
| Insect Vectors | 1 | 2017 | 4 | 0.150 |
Why?
|
| World Health Organization | 1 | 2017 | 15 | 0.150 |
Why?
|
| Guillain-Barre Syndrome | 1 | 2017 | 7 | 0.150 |
Why?
|
| Rectal Diseases | 1 | 2016 | 2 | 0.140 |
Why?
|
| Syphilis Serodiagnosis | 1 | 2016 | 4 | 0.140 |
Why?
|
| Chlamydia trachomatis | 1 | 2016 | 7 | 0.140 |
Why?
|
| Communicable Disease Control | 1 | 2016 | 15 | 0.140 |
Why?
|
| Mouth Diseases | 1 | 2016 | 21 | 0.140 |
Why?
|
| Anal Canal | 1 | 2016 | 20 | 0.140 |
Why?
|
| California | 1 | 2016 | 62 | 0.140 |
Why?
|
| Specimen Handling | 1 | 2016 | 33 | 0.140 |
Why?
|
| Cross-Over Studies | 1 | 2016 | 93 | 0.140 |
Why?
|
| North Carolina | 1 | 2020 | 1516 | 0.130 |
Why?
|
| Feasibility Studies | 1 | 2016 | 292 | 0.130 |
Why?
|
| Self Care | 1 | 2016 | 144 | 0.130 |
Why?
|
| Female | 6 | 2020 | 19916 | 0.120 |
Why?
|
| Health Status | 1 | 2017 | 399 | 0.120 |
Why?
|
| United States | 1 | 2020 | 3936 | 0.100 |
Why?
|
| Quality of Life | 1 | 2017 | 933 | 0.100 |
Why?
|
| DNA, Fungal | 1 | 2010 | 2 | 0.100 |
Why?
|
| DNA, Ribosomal | 1 | 2010 | 3 | 0.100 |
Why?
|
| Granulomatous Disease, Chronic | 1 | 2010 | 6 | 0.090 |
Why?
|
| Histocytochemistry | 1 | 2010 | 30 | 0.090 |
Why?
|
| Phylogeny | 1 | 2010 | 55 | 0.090 |
Why?
|
| Microscopy | 1 | 2010 | 26 | 0.090 |
Why?
|
| Immunocompromised Host | 1 | 2010 | 51 | 0.090 |
Why?
|
| Sequence Analysis, DNA | 1 | 2010 | 137 | 0.090 |
Why?
|
| Molecular Sequence Data | 1 | 2010 | 356 | 0.090 |
Why?
|
| Young Adult | 2 | 2016 | 2607 | 0.080 |
Why?
|
| Enterocolitis, Pseudomembranous | 1 | 2007 | 9 | 0.070 |
Why?
|
| Salmonella Infections | 1 | 2007 | 10 | 0.070 |
Why?
|
| Middle Aged | 2 | 2017 | 11845 | 0.060 |
Why?
|
| Animals | 1 | 2017 | 7459 | 0.060 |
Why?
|
| Cross-Sectional Studies | 2 | 2020 | 1527 | 0.060 |
Why?
|
| Brain | 1 | 2010 | 949 | 0.060 |
Why?
|
| Macrolides | 1 | 2020 | 6 | 0.050 |
Why?
|
| Adolescent | 2 | 2020 | 3515 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2020 | 594 | 0.040 |
Why?
|
| Mutation | 1 | 2020 | 488 | 0.040 |
Why?
|
| Loneliness | 1 | 2017 | 9 | 0.040 |
Why?
|
| Prevalence | 1 | 2020 | 981 | 0.040 |
Why?
|
| Disabled Persons | 1 | 2017 | 105 | 0.040 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2016 | 10 | 0.040 |
Why?
|
| Sex Factors | 1 | 2017 | 663 | 0.030 |
Why?
|
| Ethnic Groups | 1 | 2017 | 476 | 0.030 |
Why?
|
| Depression | 1 | 2017 | 443 | 0.030 |
Why?
|
| Smoking | 1 | 2017 | 496 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2017 | 1821 | 0.030 |
Why?
|
| Risk Factors | 1 | 2017 | 3867 | 0.020 |
Why?
|
| Ciprofloxacin | 1 | 2007 | 12 | 0.020 |
Why?
|
| Anti-Infective Agents | 1 | 2007 | 44 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2007 | 518 | 0.020 |
Why?
|